Alanine News and Research

RSS

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

13 Sep 2022

Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors

12 Sep 2022

Exposure to blue light may accelerate aging

A new study provides insights into the novel mechanisms through which blue light exposure interferes with non-retinal cell metabolic pathways in flies.

5 Sep 2022

SARS-CoV-2 mutational spectra based on reconstructed phylogenetic tree

In a new study, researchers assessed the impact of mutagenesis on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and the effects of mutations in the neutral regions and non-neutral regions of the genome.

25 Aug 2022

Surprising culprit contributes significantly to the brain destruction after stroke or TBI

In the aftermath of a stroke or TBI, a group of amino acids that typically support brain function contribute significantly to the brain destruction that can follow both these injuries, scientists report.

23 Aug 2022

What is the impact of COVID-19 on maternal, fetal, and neonatal characteristics?

In a new study, researchers assessed the impact of early onset COVID-19 on maternal, fetal, and neonatal characteristics.

16 Aug 2022

Review of natural products with promising anti-SARS-CoV-2 potential

In a new study, researchers reviewed existing literature on naturally active products with therapeutic efficacy against SARS-CoV-2.

10 Aug 2022

Scientists conduct comparative analysis of monkeypox virus profilin-like proteins and human profilin proteins

In a new study, researchers explored monkeypox virus proteomics and structural characteristics of the A42R protein, the only MPXV protein in the RCSB PDB (protein data bank) and the only profilin-like protein of poxviruses with known structure.

10 Aug 2022

Researchers unravel the mechanism of teixobactin at the atomic level

Researchers explored the mechanisms underlying the bactericidal action of teixobactin at an atomic level.

8 Aug 2022

Mice study reveals hepatic consequences of exposure to endocrine disrupting chemical mixtures

We are increasingly being exposed to endocrine-disrupting chemicals (EDCs) that interfere with the normal functioning of our hormones. Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans, pharmaceuticals, and cosmetics, are well-known EDCs.

4 Aug 2022

Case series of first 3 monkeypox patients in Massachusetts treated with tecoviromat

A team of US-based scientists has described the therapeutic efficacy of a pan-Orthopoxvirus inhibitor, tecovirimat, in patients with monkeypox infection

3 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Scientists explore guanine-specific pocket in SARS-CoV-2 nucleocapsid protein of therapeutic value against multiple coronaviruses

Researchers studied open and closed conformations of the C-terminal of SARS-CoV-2 nucleocapsid (N) protein termed the NCTD.

19 Jul 2022

The role of FTIR in protein analysis and biomedical applications

Professor Dr. Werner Mantele is the Professor of Biophysics at Goethe University and Frankfurt University. With over 30 years of experience with spectroscopy, Dr. Mantele is an internationally-recognized expert in the analysis and detection of molecules.

From Thermo Fisher Scientific – Materials & Structural Analysis 18 Jul 2022

How common is pediatric cannabis use and what are the risks?

New research evaluated the recent usage of marijuana and its derivative products, their effects and clinical manifestations, perceptions, pharmaceutics, epidemiological studies, and the long-term ramifications in pediatric populations.

12 Jul 2022

Clinical presentation of monkeypox infection in two Israeli males

Researchers described the symptomatology and clinical manifestations of monkeypox infections among two Israeli patients.

12 Jul 2022

DZNE and Intravacc receive € 2.5 million EU funding to develop a prototype ALS vaccine

DZNE and Intravacc B.V., a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines, have been awarded a funding of € 2.5 million from the European Union (EIC Transition Grant) to further develop a prototype ALS vaccine, including process development, scale-up, and toxicology study.

6 Jul 2022

Synthetic molecule Pep19 helps regulate and balance key metabolic functions, study shows

A study conducted at the University of São Paulo in Brazil shows that the synthetic molecule Pep19 acts on the endocannabinoid system, which helps regulate and balance key metabolic functions, such as appetite, fat breakdown (lipolysis), and energy release.

5 Jul 2022

Patient-derived antibody cocktail active across SARS-CoV-2 variants of concern

In a recent study published in the journal Science Immunology, researchers in the United States described a rare anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) three antibody cocktail IMM-BCP-01.

4 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022